

27<sup>th</sup> July, 2021

<b>BSE Limited</b> Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001  <b><u>Scrip Code: 532300</u></b>	<b>National Stock Exchange of India Limited</b> Listing Department Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051  <b><u>NSE Symbol – WOCKPHARMA</u></b>
-------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/ Madam,

**Sub: Press Release**

Please find enclosed herewith proposed Press Release titled “**Hugely successful vaccination roll out made possible by UK - Indian business partnership**”

Kindly take the above information on record.

Thanking you,

For **Wockhardt Limited**



**Debashis Dey**  
**Company Secretary**

Encl: As above



**Mumbai, 27<sup>th</sup> July 2021**

## **Hugely successful vaccination roll out made possible by UK - Indian business partnership**

The High Commissioner of India, Gaitri Issar Kumar visited Wockhardt UK yesterday at its pioneering sterile pharmaceutical manufacturing facility in Wrexham, North Wales.

The visit was part of a tour of Indian backed or supported businesses in the United Kingdom, and Wockhardt UK is a subsidiary of global firm Wockhardt Limited based in Mumbai.

As part of her visit, The High Commissioner was provided with a tour of the state-of-the-art vaccine fill finish facility which is currently contracted by the UK Government to manufacture the Oxford/AstraZeneca COVID-19 vaccine until August 2022.

The High Commissioner was joined by the Indian Honorary Consul for Wales, Raj Aggarwal OBE, RNR.

Her Excellency Mrs. Gaitri Issar Kumar said, “The United Kingdom’s vaccination programme has been a beacon for the world in many ways. It is a matter of great satisfaction that an India-UK collaboration in vaccine manufacture here in the UK has played a vital part in the roll out. The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector.”

Dr Habil Khorakiwala, Founder Chairman of Wockhardt emphasised, “The COVID-19 pandemic has been a challenge for all and it needed a concerted effort to overcome. We are proud to be an Indian-led company working in collaboration with the UK government with our innovative international operations in Wales. It is an honour to be recognised for our capability and commitment by the visit from the Indian High Commissioner to the UK, Gaitri Issar Kumar.”

Dr Murtaza Khorakiwala, Managing Director and Global CEO of Wockhardt added, “We were honoured to have a visit from the High Commissioner of India to recognise our India-UK collaboration and essential role in mitigating the global impact of COVID-19.”

Ravi Limaye, Managing Director of Wockhardt UK commented, “It was an honour to share our pride in the delivery of the vaccine programme to the High Commissioner, Gaitri Issar Kumar and to demonstrate the impact that Indian-led pharmaceutical innovation is having in the global fight against the COVID-19 pandemic.”

Ms Kumar’s visit is the latest one in a series of high-profile VIP attendances at the Wockhardt UK site, HRH Prince Charles and the UK Prime Minister Boris Johnson have also visited Wockhardt UK to witness the fill finish production of the vaccines.

## **About Wockhardt:**

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.

Wockhardt employs over 5,000 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 82% of its global revenues coming from international businesses.

Wockhardt UK specialises in the supply of generic and speciality medicines and is one of the leading suppliers to the NHS. They have a portfolio of over 250 product lines which are available in a wide range of preparations, including tablets, capsules, injections and liquid medicines.

The UK manufacturing site based in Wrexham, North Wales manufactures a number of sterile injectable products covering a wide range of therapy areas including diabetes, anticoagulation and pain management. The products are available in many forms such as vials, cartridges and ampoules including lyophilised (dry powder) products. In addition to their own Wockhardt branded products, they also provide contract manufacturing services for companies all around the world.